Miglustat: A review of its use in Niemann-Pick disease type C

Drugs

Volumn 74, Issue 1, 2014, Pages 61-74

  Lyseng Williamson, Katherine A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BRAZAVES; MIGLUSTAT; UNCLASSIFIED DRUG; 1 DEOXYNOJIRIMYCIN; ENZYME INHIBITOR;

ABDOMINAL PAIN; CLINICAL TRIAL; COHORT ANALYSIS; DIARRHEA; DISEASE COURSE; FLATULENCE; HUMAN; LANGUAGE; MOBILIZATION; NEUROLOGIC DISEASE; NIEMANN PICK DISEASE; NONHUMAN; RETROSPECTIVE STUDY; REVIEW; SACCADIC EYE MOVEMENT; ANALOGS AND DERIVATIVES; ANIMAL; ENZYMOLOGY; NIEMANN-PICK DISEASE, TYPE C;

1-DEOXYNOJIRIMYCIN; ANIMALS; ENZYME INHIBITORS; HUMANS; NIEMANN-PICK DISEASE, TYPE C;

EID: 84893094595     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0164-6     Document Type: Review

References (84)

1. Patterson MC, Hendriksz CJ, Walterfang M, et al. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol Genet Metab. 2012;106(3):330-44.
2. Vanier MT. Niemann-Pick disease type C. Orphanet J Rare Dis. 2010;5:16.
3. Park WD, O'Brien JF, Lundquist PA, et al. Identification of 58 novel mutations in Niemann-Pick disease type C: correlation with biochemical phenotype and importance of PTC1-like domains in NPC1. Hum Mutat. 2003;22(4):313-25.
4. Fernandez-Valero EM, Ballart A, Iturriaga C, et al. Identification of 25 new mutations in 40 unrelated Spanish Niemann-Pick type C patients: genotype-phenotype correlations. Clin Genet. 2005;68(3):245-54.
5. Macías-Vidal J, Rodríguez-Pascau L, Sánchez- Ollé G, et al. Molecular analysis of 30 Niemann-Pick type C patients from Spain. Clin Genet. 2011;80(1):39-49.
6. Fancello T, Dardis A, Rosano C, et al. Molecular analysis of NPC1 and NPC2 gene in 34 Niemann-Pick C Italian patients: identification and structural modeling of novel mutations. Neurogenetics. 2009;10(3):229-39.
7. Mavridou I, Cozar M, Douzgou S, et al. Niemann Pick type C disease: a novel NPC1 mutation segregating in a Greek island. Clin Genet. doi: 10.1111/cge.12200 [Epub 22 May 2013].
8. Bauer P, Balding DJ, Klünemann HH, et al. Genetic screening for Niemann-Pick disease type C in adults with neurological and psychiatric symptoms: findings from the ZOOM study. Hum Mol Genet. 2013;22(21):4349-56.
9. Platt FM, Boland B, van der Spoel AC. Lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J Cell Biol. 2012;199(5):723-34.
10. Madra M, Sturley SL. Niemann-Pick type C pathogenesis and treatment: from statins to sugars. Clin Lipidol. 2010;5(3):387-95.
11. Rosenbaum AI, Maxfield FR. Niemann-Pick type C disease: molecular mechanisms and potential therapeutic approaches. J Neurochem. 2011;116(5):789-95.
12. Imrie J, Dasgupta S, Besley GTN, et al. The natural history of Niemann-Pick disease type C in the UK. J Inherit Metab Dis. 2007;30(1):51-9.
13. Iturriaga C, Pineda M, Fernández-Valero EM, et al. Niemann-Pick C disease in Spain: clinical spectrum and development of a disability scale. J Neurol Sci. 2006;249(1):1-6.
14. Patterson MC, Mengel E, Wijburg FA, et al. Disease and patient characteristics in NP-C patients: findings from an international disease registry. [Erratum appears in Orphanet J Rare Dis. 2013;8:73]. Orphanet J Rare Dis. 2013;8:12.
15. Wraith JE, Guffon N, Rohrbach M, et al. Natural history of Niemann-Pick disease type C in a multicentre observational retrospective cohort study. Mol Genet Metab. 2009;98(3):250-4.
16. Sevin M, Lesca G, Baumann N, et al. The adult form of Niemann-Pick disease type C. Brain. 2007;130(Pt 1):120-33.
17. Wraith JE, Imrie J. New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat. Ther Clin Risk Manag. 2009;5(1):877-87.
18. Wraith JE, Sedel F, Pineda M, et al. Niemann-Pick type C Suspicion Index tool: analyses by age and association of manifestations. J Inherit Metab Dis. doi: 10.1007/s10545-013-9626-y [Epub 21 Jun 2013].
19. Jiang X, Sidhu R, Porter FD, et al. A sensitive and specific LC-MS/MS method for rapid diagnosis of Niemann-Pick C1 disease from human plasma. J Lipid Res. 2011;52(7):1435-45.
20. Porter FD, Scherrer DE, Lanier MH, et al. Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med. 2010;2(56):56ra81.
21. Polo G, Burlina AP, Giordano L, et al. Early diagnosis of Niemann-Pick C type 2 (NPC-2) disease by oxysterols measurement [abstract no. P-603]. J Inherit Metab Dis. 2013;36(2 Suppl):S270.
22. Reunert J, Kannenberg F, Fobker M, et al. Niemann Pick type C: improved diagnostics by oxysterol measurement [abstract no. P-625]. J Inherit Metab Dis. 2013;36(2 Suppl):S276.
23. Zavesca 100 mg hard capsules: summary of product characteristics. London: European Medicines Agency; 2013.
24. Lachmann RH, Platt FM. Substrate reduction therapy for glycosphingolipid storage disorders. Expert Opin Investig Drugs. 2001;10(3):455-66.
25. Platt FM, Neises GR, Karlsson GB, et al. N-Butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligiosaccharide processing. J Biol Chem. 1994;269(43):27108-14.
26. Platt FM, Neises GR, Dwek RA, et al. N-Butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem. 1994;269(11):8362-5.
27. Zervas M, Somers KL, Thrall MA, et al. Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr Biol. 2001;11(16):1283-7.
28. te Vruchte D, Lloyd-Evans E, Veldman RJ, et al. Accumulation of glycosphingolipids in Niemann-Pick C disease disrupts endosomal transport. J Biol Chem. 2004;279(25):26167-75.
29. Lachmann RH, Te Vruchte D, Lloyd-Evans E, et al. Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C. Neurobiol Dis. 2004;16(3):654-8.
30. Maalouf K, Das AM, Naim HY. M. Niemann-Pick type C: restoration of lipid rafts and other biochemical anomalies by N-butyl-deoxinojirimycin [abstract no. P-347]. J Inherit Metab Dis. 2011;34(Suppl 3):S193.
31. Ribas GS, Pires R, Coelho JC, et al. Oxidative stress in Niemann-Pick type C patients: a protective role of N-butyl-deoxynojirimycin therapy. Int J Dev Neurosci. 2012;30(6):439-44.
32. Fu R, Yanjanin NM, Bianconi S, et al. Oxidative stress in Niemann-Pick disease, type C. Mol Genet Metab. 2010;101(2-3):214-8.
33. Rodríguez-Sureda V, Irún P, Sánchez O, et al. Molecular oxidative stress in Niemann-Pick disease type C [abstract no. P-624]. J Inherit Metab Dis. 2013;36(2 Suppl):S275.
34. Mattsson N, Zetterberg H, Bianconi S, et al. γ-Secretase-dependent amyloid-β is increased in Niemann-Pick type C: a cross-sectional study. Neurology. 2011;76(4):366-72.
35. Mattsson N, Zetterberg H, Bianconi S, et al. Miglustat treatment may reduce cerebrospinal fluid levels of the axonal degeneration marker tau in Niemann-Pick type C. JIMD Rep. 2012;3:45-52.
36. Amiri M, Naim HY. Miglustat-induced intestinal carbohydrate malabsorption is due to the inhibition of α-glucosidases, but not β- galactosidases. J Inherit Metab Dis. 2012;35(6):949-54.
37. van der Spoel AC, Jeyakumar M, Butters TD, et al. Reversible infertility in male mice after oral administration of alkylated imino sugars: a nonhormonal approach to male contraception. Proc Natl Acad Sci USA. 2002;99(26):17173-8.
38. Suganuma R, Walden CM, Butters TD, et al. Alkylated imino sugars, reversible male infertility-inducing agents, do not affect the genetic integrity of male mouse germ cells during short-term treatment despite induction of sperm deformities. Biol Reprod. 2005;72(4):805-13.
39. Walden CM, Butter TD, Dwek RA, et al. Long-term non-hormonal male contraception in mice using N-butyldeoxynojirimycin. Hum Reprod. 2006;21(5):1309-15.
40. Amory JK, Muller CH, Page ST, et al. Miglustat has no apparent effect on spermatogenesis in normal men. Hum Reprod. 2007;22(3):702-7.
41. van Giersbergen PLM, Dingemanse J. Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase. J Clin Pharmacol. 2007;47(10):1277-82.
42. Treiber A, Morand O, Clozel M. The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica. 2007;37(3):298-314.
43. Patterson MC, Vecchio D, Prady H, et al. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007;6(9):765-72.
44. Wraith JE, Vecchio D, Jacklin E, et al. Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. Mol Genet Metab. 2010;99(4):351-7.
45. Patterson MC, Vecchio D, Jacklin E, et al. Long-term miglustat therapy in children with Niemann-Pick disease type C. J Child Neurol. 2010;25(3):300-5.
46. Pineda M, Wraith JE, Mengel E, et al. Miglustat in patients with Niemann-Pick disease Type C (NP-C): a multicenter observational retrospective cohort study. Mol Genet Metab. 2009;98(3):243-9.
47. Pineda M, Mengel E, Wijburg FA, et al. Longitudinal outcomes from the international disease registry for Niemann-Pick disease type C (NP-C) [abstract no. P-579 plus poster presented at the 12th International Congress of Inborn Errors of Metabolism, 3-6 Sep 2013, Barcelona]. J Inherit Metab Dis. 2013;36(2 Suppl):S263.
48. Abi-Warde MT, Barth M, Brassier A, et al. Pediatric Niemann Pick C disease: clinical and MRI outcome using tensor diffusion imaging (DTI) in a series of 11 pediatric patients, 6 of them treated with miglustat [abstract no. P-346]. J Inherit Metab Dis. 2011;34(Suppl 3):S193.
49. Bandeira A, Morais L, Santos M, et al. One year treatment with miglustat in infantile Niemann-pick type C [abstract no. 470-P]. J Inherit Metab Dis. 2010;33(Suppl 1):S147.
50. Chien YH, Peng SF, Yang CC, et al. Long-term efficacy of miglustat in paediatric patients with Niemann-Pick disease type C. J Inherit Metab Dis. 2013;36(1):129-37.
51. Fecarotta S, Amitrano M, Romano A, et al. The videofluoroscopic swallowing study shows a sustained improvement of dysphagia in children with Niemann-Pick disease type C after therapy with miglustat. Am J Med Genet A. 2011;155A(3):540-7.
52. Haliloglu G, Yuce A, Gurakan F, et al. Miglustat treatment in Niemann-Pick disease type C (NP-C): clinical experience in two patients [abstract no. P05.11]. Eur J Paediatr Neurol. 2011;15(Suppl 1):S52.
53. Hasanoǧlu A, Küçükçongar A, Tümer L, et al. Use of miglustat in four children with infantile-onset Niemann-Pick disease type C [abstract no. P-629]. J Inherit Metab Dis. 2013;36(2 Suppl):S277.
54. Héron B, Valayannopoulos V, Baruteau J, et al. Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C. Orphanet J Rare Dis. 2012;7:36.
55. Karimzadeh P, Tonekaboni SH, Ashrafi MR, et al. Effects of miglustat on stabilization of neurological disorder in Niemann-Pick disease type C: Iranian pediatric case series. J Child Neurol. 2013;28(12):1599-606.
56. Kolnikova M, Sykora P, Behulova D. Efficacy and tolerability of miglustat in patients with Niemann-Pick C disease [abstract no. P05.1]. Eur J Paediatr Neurol. 2011;15(Suppl 1):S49.
57. Paciorkowski AR, Westwell M, Ounpuu S, et al. Motion analysis of a child with Niemann-Pick disease type C treated with miglustat. Mov Disord. 2008;23(1):124-8.
58. Pérez-Poyato MS, Gordo MM, Marfa MP. Initiation and discontinuation of substrate inhibitor treatment in patients with Niemann-Pick type C disease. Gene. 2012;506(1):207-10.
59. Pineda M, Perez-Poyato MS, O'Callaghan M, et al. Clinical experience with miglustat therapy in pediatric patients with Niemann-Pick disease type C: a case series. Mol Genet Metab. 2010;99(4):358-66.
60. Santos ML, Raskin S, Telles DS, et al. Treatment of a child diagnosed with Niemann-Pick disease type C with miglustat: a case report in Brazil. J Inherit Metab Dis. 2008;31(Suppl 2):S357-61.
61. Skorpen J, Helland IB, Tennoe B. Use of miglustat in a child with late-infantile-onset Niemann-Pick disease type C and frequent seizures: a case report. J Med Case Rep. 2012;6(1):383.
62. Sreekantam S, Simmons L, Santra S, et al. Effect of miglustat on neurological outcome in early infantile niemann pick C: a case report [abstract no. P-701]. J Inherit Metab Dis. 2013;36(2 Suppl):S295.
63. Tektürk P, Guzel V, Yapici Z, et al. A child with Niemann-Pick type C presenting with antiepileptic drug-resistant epilepsy and treatment with miglustat [abstract no. P820]. J Neurol. 2011;258(1 Suppl):S231.
64. Zarowski M, Steinborn B, Gurda B, et al. Treatment of cataplexy in Niemann-Pick disease type C with the use of miglustat. Eur J Paediatr Neurol. 2011;15(1):84-7.
65. Canda E, Kagnici M, Kose M, et al. Follow-up of Niemann Pick type C patients: Ege University experience [abstract no. P-675]. J Inherit Metab Dis. 2013;36(2 Suppl):S288.
66. Fecarotta S, Astarita L, Bruschini D, et al. Efficacy of miglustat on the neurological involvement in Italian patients with Niemann-Pick disease type C [abstract]. Mol Genet Metab. 2009;98(1-2):70.
67. Galanaud D, Tourbah A, Lehericy S, et al. 24 month-treatment with miglustat of three patients with Niemann-Pick disease type C: follow up using brain spectroscopy. Mol Genet Metab. 2009;96(2):55-8.
68. Ginocchio VM, D'Amico A, Bertini E, et al. Efficacy of miglustat in Niemann-Pick C disease: a single centre experience. Mol Genet Metab. 2013;110(3):329-35.
69. Jacklin E, Imrie J, Jones S, et al. Review of 11 patients with NPC1 treated with miglustat [abstract no. 70]. Mol Genet Metab. 2010;99(2):S22.
70. Jamrozik Z, Szczudlik P, Lugowska A, et al. A case report of 'variant' biochemical phenotype of Niemann-Pick C disease and a discussion of therapeutic options. Neurol Neurochir Pol. 2013;47(1):86-9.
71. Jesús S, Cáceres-Redondo MT, Carrillo F, et al. The adult form of Niemann-Pick type C with the biochemical variant mutation on treatment with miglustat [abstract no. 330]. Mov Disord. 2013;28(Suppl 1):S121.
72. Lourenco CM, Linden VD, Camelo JS, et al. Substrate reduction therapy in the treatment of neurolipidoses: Niemann-pick type C as a paradigm [abstract no. 421-P]. J Inherit Metab Dis. 2010;33(Suppl 1):S133.
73. Sedel F, Audoin B, Chabrol B, et al. Follow up using NMR spectroscopy of 13 adult Niemann Pick C patients treated with Zavesca [abstract no. O-069]. J Inherit Metab Dis. 2011;34(3 Suppl):S259.
74. Di Rocco M, Dardis A, Madeo A, et al. Early miglustat therapy in infantile Niemann-Pick disease type C. Pediatr Neurol. 2012;47(1):40-3.
75. Walterfang M, Abel LA, Desmond P, et al. Cerebellar volume correlates with saccadic gain and ataxia in adult Niemann-Pick type C. Mol Genet Metab. 2013;108(1):85-9.
76. Walterfang M, Patenaude B, Abel LA, et al. Subcortical volumetric reductions in adult Niemann-Pick disease type C: a cross-sectional study. AJNR Am J Neuroradiol. 2013;34(7):1334-40.
77. Walterfang M, Macfarlane MD, Looi JC, et al. Pontine-to-midbrain ratio indexes ocular-motor function and illness stage in adult Niemann-Pick disease type C. Eur J Neurol. 2012;19(3):462-7.
78. Walterfang M, Fahey M, Abel L, et al. Size and shape of the corpus callosum in adult Niemann-Pick type C reflects state and trait illness variables. AJNR Am J Neuroradiol. 2011;32(7):1340-6.
79. Walterfang M, Fahey M, Desmond P, et al. White and gray matter alterations in adults with Niemann-Pick disease type C: a cross-sectional study. Neurology. 2010;75(1):49-56.
80. Scheel M, Abegg M, Lanyon LJ, et al. Eye movement and diffusion tensor imaging analysis of treatment effects in a Niemann-Pick Type C patient. Mol Genet Metab. 2010;99(3):291-5.
81. Belmatoug N, Burlina A, Giraldo P, et al. Gastrointestinal disturbances and their management in miglustat-treated patients. J Inherit Metab Dis. 2011;34(5):991-1001.
82. ® product availability and regulatory status. 2013. http://www.1.actelion.com/en/ healthcare-professionals/products/zavesca/product-availability-and-regulatory- status.page ? Accessed 11 Sep 2013.
83. Abel LA, Bowman EA, Velakoulis D, et al. Saccadic eye movement characteristics in adult Niemann-Pick Type C disease: relationships with disease severity and brain structural measures. PLoS ONE. 2012;7(11):e50947.
84. Walterfang M, Chien Y-H, Imrie J, et al. Dysphagia as a risk factor for mortality in Niemann-Pick disease type C: systematic literature review and evidence from studies with miglustat. Orphanet J Rare Dis. 2012;7:76.